Search

Your search keyword '"Vanlemmens, C"' showing total 168 results
Start Over Author "Vanlemmens, C"
168 results on '"Vanlemmens, C"'

2. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool

Author

Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., Paul L. J., Piñero, F, Costentin, C, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Carrilho, F, Cherqui, D, Burra, P, Van Vlierberghe, H, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Costa, P, de Ataide, E, Quiñones, E, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Podestá, L, Mccormack, L, Mattera, J, Gadano, A, Parente García, J, Magini, G, Miglioresi, L, Gambato, M, D'Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Piñero F., Costentin C., Degroote H., Notarpaolo A., Boin I. F., Boudjema K., Baccaro C., Chagas A., Bachellier P., Ettorre G. M., Poniachik J., Muscari F., Dibenedetto F., Duque S. H., Salame E., Cillo U., Marciano S., Vanlemmens C., Fagiuoli S., Carrilho F., Cherqui D., Burra P., Van Vlierberghe H., Lai Q., Silva M., Rubinstein F., Duvoux C., Conti F., Scatton O., Bernard P. H., Francoz C., Durand F., Dharancy S., Woehl M. l., Laurent A., Radenne S., Dumortier J., Abergel A., Barbier L., Houssel-Debry P., Pageaux G. P., Chiche L., Deledinghen V., Hardwigsen J., Gugenheim J., altieri M., Hilleret M. N., Decaens T., Costa P., de Ataide E. C., Quiñones E., Anders M., Varón A., Zerega A., Soza A., Machaca M. P., Arufe D., Menéndez J., Zapata R., Vilatoba M., Muñoz L., Menéndez R. C., Maraschio M., Podestá L. G., McCormack L., Mattera J., Gadano A., Parente García J. H., Magini G., Miglioresi L., Gambato M., D'Ambrosio C., Vitale A., Colledan M., Pinelli D., Magistri P., Vennarecci G., Colasanti M., Giannelli V., Pellicelli A., Eduard C., Samuele I., Jeroen D., Jonas S., Jacques P., Chris V., Dirk Y., Peter M., Valerio L., Christophe M., Olivier D., Jean D., Roberto T., and Paul L. J.

Abstract

Background & Aims: Two recently developed composite models, the alpha-fetoprotein (AFP) score and Metroticket 2.0, could be used to select patients with hepatocellular carcinoma (HCC) who are candidates for liver transplantation (LT). The aim of this study was to compare the predictive performance of both models and to evaluate the net risk reclassification of post-LT recurrence between them using each model's original thresholds. Methods: This multicenter cohort study included 2,444 adult patients who underwent LT for HCC in 47 centers from Europe and Latin America. A competing risk regression analysis estimating sub-distribution hazard ratios (SHRs) and 95% CIs for recurrence was used (Fine and Gray method). Harrell's adapted c-statistics were estimated. The net reclassification index for recurrence was compared based on each model's original thresholds. Results: During a median follow-up of 3.8 years, there were 310 recurrences and 496 competing events (20.3%). Both models predicted recurrence, HCC survival and survival better than Milan criteria (p <0.0001). At last tumor reassessment before LT, c-statistics did not significantly differ between the two composite models, either as original or threshold versions, for recurrence (0.72 vs. 0.68; p = 0.06), HCC survival, and overall survival after LT. We observed predictive gaps and overlaps between the model's thresholds, and no significant gain on reclassification. Patients meeting both models (“within-ALL”) at last tumor reassessment presented the lowest 5-year cumulative incidence of HCC recurrence (7.7%; 95% CI 5.1-11.5) and higher 5-year post-LT survival (70.0%; 95% CI 64.9-74.6). Conclusions: In this multicenter cohort, Metroticket 2.0 and the AFP score demonstrated a similar ability to predict HCC recurrence post-LT. The combination of these composite models might be a promising clinical approach. Impact and implications: Composite models were recently proposed for the selection of liver transplant (LT

Published
2023

5. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria

Author

Degroote, H, Piñero, F, Costentin, C, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Di Benedetto, F, Duque, S, Salame, E, Cillo, U, Gadano, A, Vanlemmens, C, Fagiuoli, S, Rubinstein, F, Burra, P, Cherqui, D, Silva, M, Van Vlierberghe, H, Duvoux, C, Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, Duvoux C, Degroote, H, Piñero, F, Costentin, C, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Chagas, A, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Di Benedetto, F, Duque, S, Salame, E, Cillo, U, Gadano, A, Vanlemmens, C, Fagiuoli, S, Rubinstein, F, Burra, P, Cherqui, D, Silva, M, Van Vlierberghe, H, Duvoux, C, Degroote H, Piñero F, Costentin C, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Di Benedetto F, Duque SH, Salame E, Cillo U, Gadano A, Vanlemmens C, Fagiuoli S, Rubinstein F, Burra P, Cherqui D, Silva M, Van Vlierberghe H, and Duvoux C

Abstract

Background & Aims: Good outcomes after liver transplantation (LT) have been reported after successfully downstaging to Milan criteria in more advanced hepatocellular carcinoma (HCC). We aimed to compare post-LT outcomes in patients receiving locoregional therapies (LRT) before LT according to Milan criteria and University of California San Francisco downstaging (UCSF-DS) protocol and ‘all-comers’. Methods: This multicentre cohort study included patients who received any LRT before LT from Europe and Latin America (2000–2018). We excluded patients with alpha-foetoprotein (AFP) above 1,000 ng/ml. Competing risk regression analysis for HCC recurrence was conducted, estimating subdistribution hazard ratios (SHRs) and corresponding 95% CIs. Results: From 2,441 LT patients, 70.1% received LRT before LT (n = 1,711). Of these, 80.6% were within Milan, 12.0% within UCSF-DS, and 7.4% all-comers. Successful downstaging was achieved in 45.2% (CI 34.8–55.8) and 38.2% (CI 25.4–52.3) of the UCSF-DS group and all-comers, respectively. The risk of recurrence was higher for all-comers (SHR 6.01 [p <0.0001]) and not significantly higher for the UCSF-DS group (SHR 1.60 [p = 0.32]), compared with patients remaining within Milan. The all-comers presented more frequent features of aggressive HCC and higher tumour burden at explant. Among the UCSF-DS group, an AFP value of ≤20 ng/ml at listing was associated with lower recurrence (SHR 2.01 [p = 0.006]) and better survival. However, recurrence was still significantly high irrespective of AFP ≤20 ng/ml in all-comers. Conclusions: Patients within the UCSF-DS protocol at listing have similar post-transplant outcomes compared with those within Milan when successfully downstaged. Meanwhile, all-comers have a higher recurrence and inferior survival irrespective of response to LRT. Additionally, in the UCSF-DS group, an ALP of ≤20 ng/ml might be a novel tool to optimise selection of candidates for LT. Clinical trial number: This study was r

Published
2021

6. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation

Author

Costentin, C, Piñero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podestá, L, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Hoyos Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Burra, P, Van Vlierberghe, H, Cherqui, D, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Chagas, A, Costa, P, Cristina de Ataide, E, Quiñones, E, Duque, S, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Mccormack, L, Mattera, J, Gadano, A, Fatima Boin, I, Parente García, J, Carrilho, F, Magini, G, Miglioresi, L, Gambato, M, Benedetto, F, D’Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Vlierberghe, H, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Costentin, Charlotte, Piñero, Federico, Degroote, Helena, Notarpaolo, Andrea, Boin, Ilka F., Boudjema, Karim, Baccaro, Cinzia, Podestá, Luis G., Bachellier, Philippe, Ettorre, Giuseppe Maria, Poniachik, Jaime, Muscari, Fabrice, Dibenedetto, Fabrizio, Hoyos Duque, Sergio, Salame, Ephrem, Cillo, Umberto, Marciano, Sebastian, Vanlemmens, Claire, Fagiuoli, Stefano, Burra, Patrizia, Van Vlierberghe, Hans, Cherqui, Daniel, Lai, Quirino, Silva, Marcelo, Rubinstein, Fernando, Duvoux, Christophe, Conti, Filomena, Scatton, Olivier, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine., Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka SF., Parente García, Jose Huygens, Carrilho, Flair, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Benedetto, Fabrizio Di, D’Ambrosio, Cecilia, Vitale, Alessandro, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Vlierberghe, Hans Van, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, Paul, Lerut Jan, Costentin, C, Piñero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podestá, L, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Hoyos Duque, S, Salame, E, Cillo, U, Marciano, S, Vanlemmens, C, Fagiuoli, S, Burra, P, Van Vlierberghe, H, Cherqui, D, Lai, Q, Silva, M, Rubinstein, F, Duvoux, C, Conti, F, Scatton, O, Bernard, P, Francoz, C, Durand, F, Dharancy, S, Woehl, M, Laurent, A, Radenne, S, Dumortier, J, Abergel, A, Barbier, L, Houssel-Debry, P, Pageaux, G, Chiche, L, Deledinghen, V, Hardwigsen, J, Gugenheim, J, Altieri, M, Hilleret, M, Decaens, T, Chagas, A, Costa, P, Cristina de Ataide, E, Quiñones, E, Duque, S, Anders, M, Varón, A, Zerega, A, Soza, A, Machaca, M, Arufe, D, Menéndez, J, Zapata, R, Vilatoba, M, Muñoz, L, Menéndez, R, Maraschio, M, Mccormack, L, Mattera, J, Gadano, A, Fatima Boin, I, Parente García, J, Carrilho, F, Magini, G, Miglioresi, L, Gambato, M, Benedetto, F, D’Ambrosio, C, Vitale, A, Colledan, M, Pinelli, D, Magistri, P, Vennarecci, G, Colasanti, M, Giannelli, V, Pellicelli, A, Vlierberghe, H, Eduard, C, Samuele, I, Jeroen, D, Jonas, S, Jacques, P, Chris, V, Dirk, Y, Peter, M, Valerio, L, Christophe, M, Olivier, D, Jean, D, Roberto, T, Paul, L, Costentin, Charlotte, Piñero, Federico, Degroote, Helena, Notarpaolo, Andrea, Boin, Ilka F., Boudjema, Karim, Baccaro, Cinzia, Podestá, Luis G., Bachellier, Philippe, Ettorre, Giuseppe Maria, Poniachik, Jaime, Muscari, Fabrice, Dibenedetto, Fabrizio, Hoyos Duque, Sergio, Salame, Ephrem, Cillo, Umberto, Marciano, Sebastian, Vanlemmens, Claire, Fagiuoli, Stefano, Burra, Patrizia, Van Vlierberghe, Hans, Cherqui, Daniel, Lai, Quirino, Silva, Marcelo, Rubinstein, Fernando, Duvoux, Christophe, Conti, Filomena, Scatton, Olivier, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine., Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka SF., Parente García, Jose Huygens, Carrilho, Flair, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Benedetto, Fabrizio Di, D’Ambrosio, Cecilia, Vitale, Alessandro, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Vlierberghe, Hans Van, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, and Paul, Lerut Jan

Abstract

Background & Aims: Patients with hepatocellular carcinoma (HCC) are selected for liver transplantation (LT) based on pre-LT imaging ± alpha-foetoprotein (AFP) level, but discrepancies between pre-LT tumour assessment and explant are frequent. Our aim was to design an explant-based recurrence risk reassessment score to refine prediction of recurrence after LT and provide a framework to guide post-LT management. Methods: Adult patients who underwent transplantation between 2000 and 2018 for HCC in 47 centres were included. A prediction model for recurrence was developed using competing-risk regression analysis in a European training cohort (TC; n = 1,359) and tested in a Latin American validation cohort (VC; n=1,085). Results: In the TC, 76.4% of patients with HCC met the Milan criteria, and 89.9% had an AFP score of ≤2 points. The recurrence risk reassessment (R3)-AFP model was designed based on variables independently associated with recurrence in the TC (with associated weights): ≥4 nodules (sub-distribution of hazard ratio [SHR] = 1.88, 1 point), size of largest nodule (3–6 cm: SHR = 1.83, 1 point; >6 cm: SHR = 5.82, 5 points), presence of microvascular invasion (MVI; SHR = 2.69, 2 points), nuclear grade >II (SHR = 1.20, 1 point), and last pre-LT AFP value (101–1,000 ng/ml: SHR = 1.57, 1 point; >1,000 ng/ml: SHR = 2.83, 2 points). Wolber's c-index was 0.76 (95% CI 0.72–0.80), significantly superior to an R3 model without AFP (0.75; 95% CI 0.72–0.79; p = 0.01). Four 5-year recurrence risk categories were identified: very low (score = 0; 5.5%), low (1–2 points; 15.1%), high (3–6 points; 39.1%), and very high (>6 points; 73.9%). The R3-AFP score performed well in the VC (Wolber's c-index of 0.78; 95% CI 0.73–0.83). Conclusions: The R3 score including the last pre-LT AFP value (R3-AFP score) provides a user-friendly, standardised framework to design post-LT surveillance strategies, protocols, or adjuvant therapy trials for HCC not limited to the Milan

Published
2022

8. Reassessment of the risk of recurrence (R3) after liver transplantation for HCC: validation of the R3 score and comparison with existing models

Author

Costentin, C, Pinero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podesta, L, Bachellier, P, Ettorre, GM, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, SH, Salame, E, Cillo, U, Gadano, A, Vanlemmens, C, Fagiuoli, S, Rubinstein, F, Burra, P, Van Vlierberghe, H, Cherqui, D, Silva, M, Duvoux, C, Costentin, C, Pinero, F, Degroote, H, Notarpaolo, A, Boin, I, Boudjema, K, Baccaro, C, Podesta, L, Bachellier, P, Ettorre, G, Poniachik, J, Muscari, F, Dibenedetto, F, Duque, S, Salame, E, Cillo, U, Gadano, A, Vanlemmens, C, Fagiuoli, S, Rubinstein, F, Burra, P, Van Vlierberghe, H, Cherqui, D, Silva, M, and Duvoux, C

Subjects
Cirrhosi, liver transplantation, alfa FP, HCC
Published
2021

14. Etude randomisée évaluant deux procédures de jeûne (6 versus 2 heures) avant une endoscopie digestive haute chez des patients cirrhotiques (Etude GASTROPREP)

Author

Sage, P, additional, Thévenot, T, additional, Di Martino, V, additional, Vanlemmens, C, additional, Vuitton, L, additional, Cervoni, JP, additional, D'engremont, C, additional, Fein, F, additional, Claudé, G, additional, Tchoumak, I, additional, Grillot, J, additional, Briot, C, additional, Biron, C, additional, Comiti, O, additional, Boivineau, G, additional, Emont, C, additional, Chupin, A, additional, Cazaux, D, additional, Prothe, C, additional, Deregnaucourt, T, additional, Stouvenot, M, additional, and Koch, S, additional

Published
2019
Full Text
View/download PDF

15. The Quick SOFA, a simple bedside score, identifies hospitalized cirrhotic patients with poor outcomes

Author

Cervoni, J.-P., primary, Weil, D., additional, Bureau, C., additional, Oberti, F., additional, Anty, R., additional, Louvet, A., additional, Plessier, A., additional, Rudler, M., additional, Heurgué-Berlot, A., additional, Rosa, I., additional, Talbodec, N., additional, Dao, T., additional, Ozenne, V., additional, Muel, E., additional, Richou, C., additional, Vanlemmens, C., additional, Piton, G., additional, Saas, P., additional, Martino, V.D., additional, and Thévenot, T., additional

Published
2017
Full Text
View/download PDF

16. Exchangeable copper: a reflection of the neurological severity in Wilson's disease

Author

Poujois, A., primary, Trocello, J.-M., additional, Djebrani-Oussedik, N., additional, Poupon, J., additional, Collet, C., additional, Girardot-Tinant, N., additional, Sobesky, R., additional, Habès, D., additional, Debray, D., additional, Vanlemmens, C., additional, Fluchère, F., additional, Ory-Magne, F., additional, Labreuche, J., additional, Preda, C., additional, and Woimant, F., additional

Published
2016
Full Text
View/download PDF

17. Cuivre échangeable : un reflet de la sévérité de l’atteinte extra-hépatique dans la maladie de Wilson

Author

Poujois, A., primary, Djebrani-Oussedik, N., additional, Sobesky, R., additional, Tinant, N., additional, Collet, C., additional, Habès, D., additional, Debray, D., additional, Vanlemmens, C., additional, Fluchère, F., additional, Ory-Magne, F., additional, Labreuche, J., additional, Duclos-Vallée, J.-C., additional, Poupon, J., additional, and Woimant, F., additional

Published
2016
Full Text
View/download PDF

18. Validation of 2 Explant-Based Recurrence Prognostic Models after Liver Transplantation for Hepatocellular Carcinoma in an External Cohort

Author

Costentin, C., primary, Notarpaolo, A., additional, Boudjema, K., additional, Magini, G., additional, Bachellier, P., additional, Meglioresi, L., additional, Muscari, F., additional, Gambato, M., additional, Salame, E., additional, Manenti, F., additional, Bernard, P.H., additional, D’Ambrosio, C., additional, Ettore, G.M., additional, Francoz, C., additional, Vitale, A., additional, Dharancy, S., additional, Burra, P., additional, Vanlemmens, C., additional, Fagiuoli, S., additional, Laurent, A., additional, Radenne, S., additional, Dumortier, J., additional, Hilleret, M.N., additional, Decaens, T., additional, Calderaro, J., additional, Amaddeo, G., additional, Roudot-Thoraval, F., additional, and Duvoux, C., additional

Published
2016
Full Text
View/download PDF

19. Liver Transplantation in Severe Neurological Forms of Wilson Disease; The French Experience

Author

Sobesky, R., primary, Poujois, A., additional, Brunet, A.S., additional, Broussolle, E., additional, Guillaud, O., additional, Salame, E., additional, Maillot, F., additional, Vanlemmens, C., additional, Hermeziu, B., additional, Meissner, W., additional, De Ledinghen, V., additional, Adam, R., additional, Cherqui, D., additional, Castaing, D., additional, Samuel, D., additional, Woimant, F., additional, and Vallée, J.C.D., additional

Published
2016
Full Text
View/download PDF

20. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma

Author

Decaens, T., Roudot-Thoraval, F., Badran, H., Wolf, P., Francois Durand, Adam, R., Boillot, O., Vanlemmens, C., Gugenheim, J., Dharancy, S., Bernard, P. H., Boudjema, K., Calmus, Y., Hardwigsen, J., Ducerf, C., Pageaux, G. P., Hilleret, M. N., Chazouillères, O., Cherqui, D., Mallat, A., Duvoux, C., Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de santé publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Chirurgie Générale et Transplantation Multi Organes, CHU Strasbourg, Chercheur indépendant, Rythmes Biologiques et Cancers, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'anatomie pathologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Unité de chronothérapie, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département Digestif, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital de l'Archet, Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Service de Chirurgie Hépatobiliaire et Digestive [Rennes] = Hepatobiliary and Digestive Surgery [Rennes], CHU Pontchaillou [Rennes], Foie, métabolismes et cancer, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service de Chirurgie Digestive, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Chirurgie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Département de Gastroentérologie et hépatologie, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-Hôpital Michallon, Service de chirurgie digestive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Hôpital Henri Mondor-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Male, Time Factors, MESH: Chi-Square Distribution, Kaplan-Meier Estimate, MESH: Risk Assessment, MESH: Proportional Hazards Models, Risk Factors, MESH: Liver Neoplasms, MESH: Risk Factors, MESH: Carcinoma, Hepatocellular, Milan criteria, MESH: Treatment Outcome, MESH: Middle Aged, liver transplantation, Liver Neoplasms, Cell Differentiation, hepatocellular carcinoma, Middle Aged, prognostic score, MESH: Predictive Value of Tests, MESH: Reproducibility of Results, Treatment Outcome, Female, France, MESH: Neoplasm Recurrence, Local, Algorithms, Adult, MESH: Cell Differentiation, MESH: Liver Transplantation, Carcinoma, Hepatocellular, MESH: Algorithms, Risk Assessment, Disease-Free Survival, Decision Support Techniques, Predictive Value of Tests, Humans, MESH: Patient Selection, MESH: Kaplan-Meier Estimate, Proportional Hazards Models, Retrospective Studies, Chi-Square Distribution, MESH: Humans, Patient Selection, MESH: Time Factors, Reproducibility of Results, MESH: Decision Support Techniques, MESH: Adult, MESH: Retrospective Studies, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH: ROC Curve, MESH: Male, MESH: France, ROC Curve, MESH: Disease-Free Survival, Neoplasm Recurrence, Local, MESH: Female
Abstract

International audience; AIM: To generate a new score with improved accuracy compared with Milan criteria to select patients. PATIENTS: The training cohort comprised 373 patients transplanted for hepatocellular carcinoma (HCC) between 1988 and 1998 (cohort 1). An algorithm was derived from the analysis of patient data by the proportional hazard Cox regression model. The area under the receiver operating characteristic (AUROC) was used to determine a cut-off value. The validation cohort comprised 140 patients transplanted between 1999 and 2001 (cohort 2). RESULTS: Multivariate analysis identified three predictors of 5-year tumour-free survival: tumour differentiation (P=0.02), diameter (P

Published
2011

23. Le syndrome hepatopulmonaire

Author

Thevenot, T., Pastor, Catherine, Cervoni, J-P, Jacquelinet, C., Nguyen-Khac, E., Richou, C., Heyd, B., Vanlemmens, C., Mantion, G., Di Martino, V., and Cadranel, J.

Subjects
Anoxia/physiopathology, Enzyme Inhibitors/therapeutic use, Nitric Oxide/therapeutic use, Hypertension, Pulmonary/physiopathology, NG-Nitroarginine Methyl Ester/therapeutic use, Humans, Mass Screening, Portasystemic Shunt, Surgical, Bronchodilator Agents/therapeutic use, Hepatopulmonary Syndrome/*diagnosis/physiopathology/*therapy, Methylene Blue/therapeutic use, ddc:616.0757, Liver Transplantation
Abstract

Hepatopulmonary syndrome is characterized by the presence of portal hypertension with or without cirrhosis, an increased alveolar-arterial oxygen partial pressure difference greater than or equal to 15 mm Hg, and dilated pulmonary capillaries. Hepatopulmonary syndrome is found in up to 20% of patients with cirrhosis and should be considered in any patient who develops dyspnea or hypoxemia. Contrast echocardiography is enough to make the diagnosis of hepatopulmonary syndrome. The exact pathophysiology of hepatopulmonary syndrome remains unknown but nitric oxide is an important factor underlying hepatopulmonary syndrome. Hypoxemia progressively deteriorates and worsens the prognosis of cirrhotic patients. Hypoxemic patients must be controlled regularly to optimise the timing of liver transplantation. Indeed, a preoperative PaO(2) of less than or equal to 50 mm Hg alone or in combination with an isotopic shunt fraction greater than or equal to 20% are the strongest predictors of postoperative mortality. There are currently no effective medical therapies for hepatopulmonary syndrome but garlic powder and iloprost inhalation demonstrate clinical improvements in the pre- and in the post-transplant period.

Published
2009

24. [Hepatopulmonary syndrome]

Author

Thevenot, T., Pastor, C.-M., Cervoni, J.-P., Jacquelinet, C., Nguyen-Khac, E., Richou, C., Heyd, B., Vanlemmens, C., Mantion, G., Di Martino, V., Cadranel, J., Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Agents pathogènes et inflammation - UFC (EA 4266) (API)

Subjects
MESH: Liver Transplantation, MESH: Humans, MESH: Hypertension, Pulmonary, Hypertension, Pulmonary, MESH: Anoxia, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Nitric Oxide, Bronchodilator Agents, Liver Transplantation, Methylene Blue, MESH: NG-Nitroarginine Methyl Ester, NG-Nitroarginine Methyl Ester, MESH: Enzyme Inhibitors, MESH: Nitric Oxide, Humans, Mass Screening, Portasystemic Shunt, Surgical, MESH: Portasystemic Shunt, Surgical, MESH: Bronchodilator Agents, MESH: Mass Screening, Enzyme Inhibitors, Hypoxia, MESH: Hepatopulmonary Syndrome, MESH: Methylene Blue, Hepatopulmonary Syndrome
Abstract

International audience; Hepatopulmonary syndrome is characterized by the presence of portal hypertension with or without cirrhosis, an increased alveolar-arterial oxygen partial pressure difference greater than or equal to 15 mm Hg, and dilated pulmonary capillaries. Hepatopulmonary syndrome is found in up to 20% of patients with cirrhosis and should be considered in any patient who develops dyspnea or hypoxemia. Contrast echocardiography is enough to make the diagnosis of hepatopulmonary syndrome. The exact pathophysiology of hepatopulmonary syndrome remains unknown but nitric oxide is an important factor underlying hepatopulmonary syndrome. Hypoxemia progressively deteriorates and worsens the prognosis of cirrhotic patients. Hypoxemic patients must be controlled regularly to optimise the timing of liver transplantation. Indeed, a preoperative PaO(2) of less than or equal to 50 mm Hg alone or in combination with an isotopic shunt fraction greater than or equal to 20% are the strongest predictors of postoperative mortality. There are currently no effective medical therapies for hepatopulmonary syndrome but garlic powder and iloprost inhalation demonstrate clinical improvements in the pre- and in the post-transplant period.

Published
2008

25. [Hepar lobatum carcinomatusum: a rare cause of portal hypertension complicating hepatic metastases in breast cancer]

Author

Cervoni, J.-P., Dobrin, A., Sailley, N., Chaigneau, L., Thevenot, T., Richou, C., Vanlemmens, C., Di Martino, V., Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis

Subjects
MESH: Hypertension, Portal, MESH: Humans, MESH: Middle Aged, Carcinoma, Ductal, Breast, Liver Neoplasms, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, Breast Neoplasms, Middle Aged, MESH: Carcinoma, Ductal, Breast, MESH: Liver Neoplasms, Hypertension, Portal, Humans, Female, MESH: Female, MESH: Breast Neoplasms
Abstract

National audience; SUMMARY: Hepar lobatum carcinomatosum is an acquired liver dysmorphy associated with liver metastases of carcinoma, usually breast carcinoma. It may cause portal hypertension. The pathogenesis of this condition appears to be related to multifocal occlusion of intrahepatic branches of the portal vein by neoplasic thrombi and desmoplastic changes. The prognosis is poor despite apparent tumor regression on imaging. We report a case of variceal bleeding revealing a hepar lobatum carcinomatosum. Magnetic resonance imaging supported this diagnosis which was suspected in the clinical context.

Published
2008

26. FRI-441 - Validation of 2 Explant-Based Recurrence Prognostic Models after Liver Transplantation for Hepatocellular Carcinoma in an External Cohort

Author

Costentin, C., Notarpaolo, A., Boudjema, K., Magini, G., Bachellier, P., Meglioresi, L., Muscari, F., Gambato, M., Salame, E., Manenti, F., Bernard, P.H., D’Ambrosio, C., Ettore, G.M., Francoz, C., Vitale, A., Dharancy, S., Burra, P., Vanlemmens, C., Fagiuoli, S., Laurent, A., Radenne, S., Dumortier, J., Hilleret, M.N., Decaens, T., Calderaro, J., Amaddeo, G., Roudot-Thoraval, F., and Duvoux, C.

Published
2016
Full Text
View/download PDF

28. Immunogenicity and safety of a novel adjuvanted hepatitis B candidate vaccine in liver transplant patients

Author

UCL - Autre, Nevens, Frederik, Zuckerman, JN, Burroughs, A, Jung, MC, Bayas, JM, Kallinowski, B, de la Mata, M, Duvoux, C, Neuhaus, P., Saliba, F, Buti, M, Zarski, JP, Pons, F, Vanlemmens, C, Hamtiaux, V, Stoffel, M., 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, UCL - Autre, Nevens, Frederik, Zuckerman, JN, Burroughs, A, Jung, MC, Bayas, JM, Kallinowski, B, de la Mata, M, Duvoux, C, Neuhaus, P., Saliba, F, Buti, M, Zarski, JP, Pons, F, Vanlemmens, C, Hamtiaux, V, Stoffel, M., and 39th Annual Meeting of the European-Association-for-the-Study-of-the-Liver

Published
2004

30. 465 LONG TERM RESULTS OF LIVER TRANSPLANTATION FOR WILSON'S DISEASE (WD): THE FRENCH EXPERIENCE

Author

Guilllaud, O., primary, Dumortier, J., additional, Durand, F., additional, Vanlemmens, C., additional, Calmus, Y., additional, Duvoux, C., additional, Kamar, N., additional, Lorho, R., additional, Wolf, P., additional, Bernard, P.H., additional, Pageaux, G.P., additional, Salame, E., additional, Radenne, S., additional, Gugenheim, J., additional, Lachaux, A., additional, Debray, D., additional, Hardwigsen, J., additional, Sobesky, R., additional, Chazouillere, O., additional, Ichai, P., additional, Samuel, D., additional, and Duclos-Vallee, J.-C., additional

Published
2010
Full Text
View/download PDF

31. [Comparative study of results of hepatic transplantation between 2 groups of patients: alcoholic cirrhosis versus non-alcoholic cirrhosis]

Author

Jaeck D, Fratte S, Karim Boudjema, Ellero B, Ml, Woehl-Jaegle, Vanlemmens C, Altier M, Duclos B, Vetter D, and Bachellier P

Subjects
Adult, Liver Cirrhosis, Male, Adolescent, Liver Cirrhosis, Alcoholic, Recurrence, Quality of Life, Humans, Female, Middle Aged, Aged, Liver Transplantation
Abstract

Among the patients treated for alcoholic cirrhosis, only a small group could be candidates for liver transplantation (LT). The aim of this multicentric study was to analyse the results of LT in a group of 75 patients with alcoholic cirrhosis (AC) compared with a group of 61 patients with non-alcoholic cirrhosis (NAC). Results were similar in both groups concerning survival rate and quality of life. However the ability to go back to a normal professional life was less in the AC group. The reported recurrence of alcoholic intoxication, which was around 26%, was much lower for patients who interrupted alcohol consumption during at least 3 months before L.T.

Published
1993

33. 31 LIVER TRANSPLANTATION (LT) FOR PATIENTS WITH ALCOHOLIC CIRRHOSIS (AC) WITH PROVEN ALCOHOL CONSUMPTION ON THE DAY OF THE TRANSPLANT PROCEDURE: A CASE CONTROL STUDY

Author

Altwegg, R., primary, Vanlemmens, C., additional, Bernard, P.-H., additional, Dharancy, S., additional, Wolf, P., additional, Dumortier, J., additional, Radenne, S., additional, Chazouillères, O., additional, Faillie, J.-L., additional, Navarro, F., additional, and Pageaux, G.-P., additional

Published
2009
Full Text
View/download PDF

34. CO.45 Tolérance et résultats préliminaires du sorafénib dans la récidive du carcinome hépatocellulaire après transplantation hépatique : étude cas-contrôle

Author

Dharancy, S., primary, Romano, O., additional, Wolf, P., additional, Lorho, R., additional, Pageaux, G.P., additional, de Ledinghen, V., additional, Hurtova Simson, M., additional, Vanlemmens, C., additional, Salame, E., additional, Dumortier, J., additional, Hilleret, M.N., additional, Cattan, S., additional, Mathurin, P., additional, and Pruvot, F.R., additional

Published
2009
Full Text
View/download PDF

39. CO 24-Essai multicentrique national randomisé chez des malades ayant une récidive virale C post transplantation hépatique traités par peginterféron alfa-2a et ribavirine puis ribavirine seule : résultats à 18 mois de l’étude transpeg

Author

Calmus, Y., primary, Samuel, D., additional, Pageaux, G., additional, Messner, M., additional, Wolf, P., additional, Rostaing, L., additional, Vanlemmens, C., additional, Le Treut, Y.P., additional, Dharancy, S., additional, Gugenheim, J., additional, Durand, F., additional, Néau-Cransac, M., additional, Boilot, O., additional, Chazouillères, O., additional, Samelson, L., additional, Boudjema, K., additional, and Duvoux, C., additional

Published
2006
Full Text
View/download PDF

40. CA35 - La transplantation hépatique (TH) est-elle un traitement efficace de l’alcoolodépendance chez le malade atteint de cirrhose alcoolique (CA) ? les leçons d’un essai randomisé

Author

Di Martino, V., primary, Braud, A., additional, Miguet, M., additional, Naudet-Collin, E., additional, Vanlemmens, C., additional, Becker, M.C., additional, Monnet, E., additional, Bresson-Hadni, S., additional, Mantion, G.A., additional, and Miguet, J.P., additional

Published
2004
Full Text
View/download PDF

41. 154 Immunogenicity and safety of a novel adjuvanted hepatitis B candidate vaccine in liver transplant patients

Author

Nevens, F., primary, Zuckerman, J.N., additional, Burroughs, A., additional, Jung, M.C., additional, Bayas, J.M., additional, Kallinowski, B., additional, de la Mata, M., additional, Duvoux, C., additional, Neuhaus, P., additional, Saliba, F., additional, Buti, M., additional, Zarski, J.P., additional, Pons, F., additional, Vanlemmens, C., additional, Hamtiaux, V., additional, and Stoffel, M., additional

Published
2004
Full Text
View/download PDF

48. Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial.

Author

Vanlemmens C, Di Martino V, Milan C, Messner M, Minello A, Duvoux C, Poynard T, Perarnau JM, Piquet MA, Pageaux GP, Dharancy S, Silvain C, Hillaire S, Thiefin G, Vinel JP, Hillon P, Collin E, Mantion G, Miguet JP, and TRANSCIAL Study Group

Abstract

Background: Liver transplantation improves survival of patients with end-stage (Child-Pugh stage C) alcoholic cirrhosis, but its benefit for patients with stage B disease is uncertain.Objective: To compare the outcomes of patients with Child-Pugh stage B alcoholic cirrhosis who are immediately listed for liver transplantation with those of patients assigned to standard treatment with delay of transplantation until progression to stage C disease.Design: Randomized, controlled trial.Setting: 13 liver transplantation programs in France.Patients: 120 patients with Child-Pugh stage B alcoholic cirrhosis and no viral hepatitis, cancer, or contraindication to transplantation.Interventions: Patients were randomly assigned to immediate listing for liver transplantation (60 patients) or standard care (60 patients).Measurements: Overall and cancer-free survival over 5 years.Results: Sixty-eight percent of patients assigned to immediate listing for liver transplantation and 25% of those assigned to standard care received a liver transplant. All-cause death and cirrhosis-related death did not statistically differ between the 2 groups: 5-year survival was 58% (95% CI, 43% to 70%) for those assigned to immediate listing versus 69% (CI, 54% to 80%) for those assigned to standard care. In multivariate analysis, independent predictors of long-term survival were absence of ongoing alcohol consumption (hazard ratio, 7.604 [CI, 2.395 to 24.154]), recovery from Child-Pugh stage C (hazard ratio, 7.633 [CI, 2.392 to 24.390]), and baseline Child-Pugh score less than 8 (hazard ratio, 2.664 [CI, 1.052 to 6.746]). Immediate listing for transplantation was associated with an increased risk for extrahepatic cancer: The 5-year cancer-free survival rate was 63% (CI, 43% to 77%) for patients who were immediately listed and 94% (CI, 81% to 98%) for those who received standard care.Limitation: Restriction of the study sample to alcoholic patients may limit the generalizability of results to other settings.Conclusion: Immediate listing for liver transplantation did not show a survival benefit compared with standard care for Child-Pugh stage B alcoholic cirrhosis. In addition, immediate listing for transplantation increased the risk for extrahepatic cancer.Funding: The French National Program for Clinical Research. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results